Why Attend
The Microbiome Invest Congress 2018 is dedicated to showcasing the most innovative emerging companies and academics with commercially viable research that manipulates the microbiome. Active investors, and multi-national nutrition and pharmaceutical companies will also share their knowledge and perspectives on commercialisation and discuss the most cutting-edge products and research in the microbiome space.
“The human microbiome market is expected to reach USD 658 Million by 2023 from USD 294 Million in 2019 growing at a CAGR of 22.3% during the forecast period (2019–2023)” Human Microbiome Market Industry Report – Markets and Markets
'Pitch Your Microbes' Finalists
Dominik Burziwoda
Prior to founding MillionFriends Dominik worked as Head of Operations at the German E-Commerce company Springlane. The company scaled from 8 to >100 people within 3 years. He started his career as an Investment Banker with Lincoln International and worked at Innogy on M&A and financing transactions of renewable energy plant across Europe. He graduated with an LL.M. from University of Munster, with a Master in Finance from IE Business School and holds a BSc in Business from Rotterdam School of Management. He is a passionate snowboarder and healthcare tech enthusiast.
Evelina Vågesjö, PhD MBA
Co-founder of and developed the concept during PhD 2011-2016, is now CEO and heading the drug and business development in Ilya Pharma. Also BSc in Management Accounting and finished an MBA 2018. Raised >4.3 M€ in grant funding to the project, lead the first private share issue in 2017 and designed stock option programs for key employees.
Kristofer Cook
Kristofer is a serial entrepreneur who, over the past 15 years, has co-founded six biotechnology companies in the areas of clean technology, food-technology and life science. In addition to holding multiple board positions in several private and public companies, Kristofer is currently CEO of Carbiotix, an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics, along-side a range of cost-effective gut health testing services. Kristofer holds a MSc. degree from Lund University, Sweden, and a M.B.A. degree from Solvay Business School, Belgium.
Grégory Lambert
Pharmacist and Ph.D. in pharmaceutical technology, Gregory’s carrier is split between Biotech and Pharma where he occupied the positions of Chief Scientific Officer and Chief Executive Officer. Gregory drove the development of a number of drugs, medical devices and food supplement from the laboratory to market. Since 2014, Gregory is the CEO of TargEDys.
Mats Wallstrom
Mats is an engineer by education with a special interest in what makes the body perform. He has dedicated years of development of the Qualvivo bacterial boxed-system technology.
Mats is motivated to grow a company and to introduce products on the international market. He identified a window of opportunity to develop the power of bacteria and combined partnering expertise in biotechnology with an engineering approach to develop Qualvivo.
Richard Andrews
Mr. Andrews has spent most of his career as a C level executive leading operations, finance, and commercial and clinical development for biotechnology firms focused on new products that address inflammatory disease. Mr. Andrews has been instrumental in translating research and academic discoveries into product development and advanced clinical programs, building alliances and partnerships and organizing operational teams. Financing processes led by Mr. Andrews have secured over $130M in equity funding for new ventures. His work has been primarily focused on skin disease, pneumonia, infant hypoxic ischemia and kidney failure. Early in his career, Mr. Andrews led the commercialization of several natural cell systems to prevent disease on fruits and vegetables and launched several DNA diagnostic tests for periodontal disease. Mr. Andrews received graduate degrees in physical biochemistry (MS), and technology management (SM) from Purdue University, and the Massachusetts Institute of Technology, respectively. He also has an undergraduate degree in Chemistry (BS) from Hobart College.
Gregory McKenzie, Ph.D.
Gregory McKenzie, Ph.D., Vice President and Chief Scientific Officer, has over ten years of experience developing microbial-based products and leading discovery and development teams. Greg was formerly Senior Principal Scientist at Seres Therapeutics where he was a key senior member of the teams that brought the live biotherapeutics SER-109, SER-262, and SER-287 from discovery through proof-of-concept in animals to clinical stage programs.
Dr Soren Krogsgaard Thomsen
Dr Soren Krogsgaard Thomsen is co-founder and CEO of the UK-based start-up company BioMe Oxford. Trained in medical genetics at the Universities of Oxford and Cambridge, Soren has a background in both academic and industrial life sciences research. His publication record spans work on the genetics of complex diseases and academic entrepreneurship. Since co-founding BioMe Oxford, he has successfully led the company to raising pre-seed investment, winning a number of international business competitions along the way (incl. Imagine IF and Idea Idol). Soren dreams of enabling a revolution in precision medicine through population-wide studies of our second genome within.
Dr Luis Gosalbez
Luis is the Director of Business Development at OptiBiotix Health in the UK. Previously, he held different positions in the biotechnology industry and in pharmaceutical consulting in Spain and Germany. His scientific career was developed between Universidad Complutense de Madrid, Centro de Biología Molecular Severo Ochoa-CSIC (both in Spain) and the Korea Advanced Institute of Science and Technology (KAIST, South Korea). His research was always focused on microbiology, the human microbiome and on the development of antimicrobials and antivirals. He received his BSc and MSc in Biotechnology from Universidad Complutense de Madrid, his PhD in Life Sciences from the Catholic University of San Antonio (Spain) and a Master’s in Bioscience Enterprise from the University of Cambridge in the UK.
The Speakers
Adrian Ferrero
Andrew Morgan
Dr Andrew Morgan is Chair of the UK’s KTN Microbiome Special Interest Group and has close to 40 years’ experience in health & nutrition research & innovation related to microbe-host interactions including human, animal and plant. He held the role of Chief Scientist to DuPont’s Nutrition & Health and legacy Danisco business (2008-2019) and was a DuPont Fellow. Having joined the company as a member of the pioneering FFI animal nutrition enzyme team, he then went on to play a key role in helping build DuPont’s microbiome platform. Andrew retired from DuPont at the end of 2019.
Artem Khlebinkov
Isabelle De Cremoux
David Berry
Bram Vanparys
Derek Butler
Jim Weston
Dr David Cook
David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. (“Seres”). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr. Cook was the founding CEO at Anza Therapeutics, a biotechnology startup that focused on developing a microbial vaccine platform to induce cellular immune responses. Before launching Anza, Dr. Cook held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, overseeing R&D, program management, manufacturing, and clinical and regulatory affairs. He has led teams in the development and commercialization of several biotech products and has been directly responsible for obtaining marketing authorization from the European Union for four medical products. Dr. Cook is also a co-inventor on more than 25 patents. He earned his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.
John Hambour
Luc Sterkman
Mike Romanos
Mike Romanos is a co-founder and Chief Executive of Microbiotica. He has 30 years’ experience in the biotech and pharma industry and previously co-founded Crescendo Biologics which he built and led as CEO and CSO, developing a leading antibody fragment discovery platform and pipeline in oncology and inflammation. Prior to that he held global VP roles in GlaxoSmithKline R&D over 10 years, during which time he formed and led major transnational divisions which helped shape the company’s discovery platforms and pipelines across therapeutic areas and modalities. In his last role he led a transnational group of 300 staff providing genomics, target and biomarker discovery, and platform biology for R&D. Mike is highly experienced in biotech translation and commercialisation, currently serving as a Non-Exec Director of the life-sciences charity LifeArc, and previously as Translational Adviser in Biomedicine at Imperial College, Venture Partner to UK Innovation and Science Seed Fund, and committee member on the MRC’s Developmental Pathway Funding Scheme for translational academic research. Mike holds a degree in Natural Sciences from Cambridge University, a PhD in Molecular Virology from Imperial College, and is a Fellow of the Royal Society of Biology.
Assaf Oron
Xavier Duportet
Pitch Your Microbes
Central to MICROBIOME INVEST is ‘Pitch Your Microbes’, a platform for 12 of the most exciting emerging companies in microbiome to pitch their innovative ideas to a room full of potential advisors, investors and partners. Our esteemed selection committee will handpick these final
12 presenting companies from the list of all applicants.
To apply, you should meet one of the following entry criteria:
- An academic with a desire to develop and commercialise an innovative idea or piece of research that will benefit patients.
- A recent spin-out from an academic institution looking for financial investment, partnerships and advice.
- A biotech company at the pre-revenue or post-revenue stage, looking for financial investment, partnerships, licencing deals and advice.
DEADLINE: 6th APRIL 2018
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
Media Partners
Beneficial Microbes
Website: www.wageningenacademic.com/journals/bm/general-information
Beneficial Microbes is a peer-reviewed scientific journal with a specific area of focus: the promotion of the science of microbes beneficial to the health and wellbeing of man and animal. The journal contains original research papers and critical reviews in all areas dealing with beneficial microbes in both the small and large intestine, together with opinions, a calendar of forthcoming beneficial microbes-related events and book reviews. The journal takes a multidisciplinary approach and focuses on a broad spectrum of issues, including safety aspects of pro- & prebiotics, regulatory aspects, mechanisms of action, health benefits for the host, optimal production processes, screening methods, (meta)genomics, proteomics and metabolomics, host and bacterial physiology, application, and role in health and disease in man and animal. Beneficial Microbes is intended to serve the needs of researchers and professionals from the scientific community and industry, as well as those of policy makers and regulators
Microorganisms Journal
Website: http://www.mdpi.com/journal/microorganisms
Microorganisms (ISSN 2076-2607) is an international, peer-reviewed open access journal which provides an advanced forum for studies related to prokaryotic and eukaryotic microorganisms, viruses and prions. It publishes reviews, research papers and communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. Electronic files and software regarding the full details of the calculation or experimental procedure, if unable to be published in a normal way, can be deposited as supplementary electronic material.
Microbiology Society
Website: https://microbiologysociety.org/
The Microbiology Society is a membership charity for scientists interested in microbes, their effects and their practical uses. It is one of the largest microbiology societies in Europe with a worldwide membership based in universities, industry, hospitals, research institutes and schools.
Labiotech
Website: https://labiotech.eu/
Labiotech.eu is the leading digital media covering the European Biotech industry. Over 90,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!
Contract Biotechnology
Website: https://www.contract-biotechnology.com/
Contract-Biotechnology.com is a web-based platform for external solutions for R&D projects. We connect researchers and organizations involved in research and development with service and products providers worldwide.
Our mission is to help researchers make breakthrough discoveries, providing them direct access to those contract laboratories that best fit their needs. We help them to find what they need to advance their research. WE MAKE LIFE EASY FOR RESEARCHERS
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
- Academics, Biotech companies (under 3 years old), and Investors£599 +VATStandard PricingMain ConferenceOne-to-One Meeting SchedulerPost-Show Access to PresentationsPoster SessionsComplimentary Articles and Content
- Pharmaceutical, Nutrition & Biotech companies (over 3 years old)£1,599 + VATStandard PricingMain ConferenceOne-to-One Meeting SchedulerPost-Show Access to PresentationsPoster SessionsComplimentary Articles and Content
- Vendors (including Investment bankers, Lawyers, Consultants)£1,899 + VATStandard PricingMain ConferenceOne-to-One Meeting SchedulerPost-Show Access to PresentationsPoster SessionsComplimentary Articles and Content
- Poster Session (FREE for attendees (£50 for Non-Attendees)£50 + VATStandard PricingPoster Session
Book a Team to Save More!
Industry Rates Only: Team discounts cannot be combined with any other discount or offer
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
Venue
Novotel London West, 1, Shortlands, W6 8DR, London
Room rate: £139 includes VAT and English breakfast.
To book a room telephone reservations on + 44 (0) 208 741 1555 or
Email: [email protected]
Always quote: KISACO220518
Book by 25 April 2018
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.